On the other hand, tofersen is an active ingredient in the proprietary name “Qalsody.” It is the first gene therapy approved for ALS, specifically for patients with the SOD1 genetic form of the disease, and represents a novel therapeutic intervention [19]. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.